Novel preclinical models and biomarkers for prostate cancer

被引：0
|
作者：
Korzeniewski, N. [1 ]
Tapia-Laliena, M. [1 ]
Tolstov, Y. [1 ]
Pahernik, S. [2 ]
Hadaschik, B. [2 ]
Hohenfellner, M. [2 ]
Duensing, S. [1 ,2 ]
机构：
[1] Univ Klinikum Heidelberg, Sekt Mol Uroonkol, Urol Univ Klin, D-69120 Heidelberg, Germany
[2] Univ Klinikum Heidelberg, Urol Univ Klin, D-69120 Heidelberg, Germany
来源：
UROLOGE | 2013年 / 52卷 / 09期
关键词：
Therapy; oncological; Genetically engineered mouse model; Xenograft model; Androgen ablation; Metastasization; osseous; REARRANGEMENT; MECHANISMS; FUSION;
D O I：
10.1007/s00120-013-3310-6
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The ultimate goal of a personalized approach to prostate cancer patient management relies on two prerequisites: the development of preclinical but clinically relevant model systems and robust prognostic and predictive biomarkers. The past several years have shown significant progress towards these two prerequisites which will be highlighted in this review using some notable examples.
引用
收藏
页码：1256 / 1260
页数：5
相关论文
共 50 条
  • [21] miRNAs as novel biomarkers in the management of prostate cancer
    Filella, Xavier
    Foj, Laura
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2017, 55 (05) : 715 - 736
  • [22] Noncoding RNAs as Novel Biomarkers in Prostate Cancer
    Ronnau, C. G. H.
    Verhaegh, G. W.
    Luna-Velez, M. V.
    Schalken, J. A.
    [J]. BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [23] Novel Biomarkers for Prostate Cancer Detection and Prognosis
    Filella, Xavier
    Foj, Laura
    [J]. CELL & MOLECULAR BIOLOGY OF PROSTATE CANCER: UPDATES, INSIGHTS AND NEW FRONTIERS, 2018, 1095 : 15 - 39
  • [24] Novel Diagnostic Biomarkers of Prostate Cancer: An Update
    Anceschi, Umberto
    Tuderti, Gabriele
    Lugnani, Franco
    Biava, Pier Mario
    Malossini, Gianni
    Luciani, Lorenzo
    Cai, Tommaso
    Marsiliani, Davide
    Filianoti, Alessio
    Mattevi, Daniele
    Costantini, Manuela
    Misuraca, Leonardo
    Simone, Giuseppe
    [J]. CURRENT MEDICINAL CHEMISTRY, 2019, 26 (06) : 1045 - 1058
  • [25] Prostate cancer: Novel genetic and immunologic biomarkers
    Samare-Najaf, Mohammad
    Kouchaki, Hosein
    Mahini, Seyed Moein
    Rounkian, Masoumeh Saberi
    Tavakoli, Yasaman
    Samareh, Ali
    Azadbakht, Mohammad Karim
    Jamali, Navid
    [J]. CLINICA CHIMICA ACTA, 2024, 555
  • [26] Clinical and Novel Biomarkers in the Management of Prostate Cancer
    Cristóbal Sanhueza
    Manish Kohli
    [J]. Current Treatment Options in Oncology, 2018, 19
  • [27] A NOVEL STRATEGY TO IDENTIFY BIOMARKERS FOR PROSTATE CANCER
    Scapa, J.
    Kerkoutian, S.
    Sun, Y.
    Zhang, H.
    Squires, J.
    Li, X.
    Goldstein, A.
    Witte, O.
    Huang, J.
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2013, 61 (01) : 173 - 173
  • [28] Lucap prostate cancer xenografts: clinically relevant models of prostate cancer and their use in preclinical testing
    Nguyen, H.
    Morrissey, C.
    Nelson, P.
    Zhang, X.
    Higano, C.
    Lange, P.
    True, L.
    Vessella, R.
    Corey, E.
    [J]. TUMOR BIOLOGY, 2012, 33 : 47 - 47
  • [29] Epigenetic potential of resveratrol and analogs in preclinical models of prostate cancer
    Kumar, Avinash
    Dhar, Swati
    Rimando, Agnes M.
    Lage, Janice M.
    Lewin, Jack R.
    Zhang, Xu
    Levenson, Anait S.
    [J]. RESVERATROL AND HEALTH, 2015, 1348 : 1 - 9
  • [30] Genomic Characterization of Preclinical Prostate Cancer Cell Line Models
    Beatson, Erica L.
    Risdon, Emily N.
    Napoli, Giulia C.
    Price, Douglas K.
    Chau, Cindy H.
    Figg, William D.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (11)
12345